Biogen Shares Outstanding 2010-2022 | BIIB
Biogen shares outstanding history from 2010 to 2022. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
- Biogen shares outstanding for the quarter ending March 31, 2022 were 0.148B, a 3.09% decline year-over-year.
- Biogen 2021 shares outstanding were 0.15B, a 7.25% decline from 2020.
- Biogen 2020 shares outstanding were 0.161B, a 13.93% decline from 2019.
- Biogen 2019 shares outstanding were 0.187B, a 8.72% decline from 2018.
Biogen Annual Shares Outstanding
(Millions of Shares) |
| 2021 |
150 |
| 2020 |
161 |
| 2019 |
187 |
| 2018 |
205 |
| 2017 |
213 |
| 2016 |
219 |
| 2015 |
231 |
| 2014 |
237 |
| 2013 |
238 |
| 2012 |
240 |
| 2011 |
245 |
| 2010 |
255 |
| 2009 |
289 |
Biogen Quarterly Shares Outstanding
(Millions of Shares) |
| 2022-03-31 |
148 |
| 2021-12-31 |
150 |
| 2021-09-30 |
149 |
| 2021-06-30 |
150 |
| 2021-03-31 |
152 |
| 2020-12-31 |
161 |
| 2020-09-30 |
157 |
| 2020-06-30 |
161 |
| 2020-03-31 |
173 |
| 2019-12-31 |
187 |
| 2019-09-30 |
184 |
| 2019-06-30 |
190 |
| 2019-03-31 |
197 |
| 2018-12-31 |
205 |
| 2018-09-30 |
202 |
| 2018-06-30 |
207 |
| 2018-03-31 |
212 |
| 2017-12-31 |
213 |
| 2017-09-30 |
212 |
| 2017-06-30 |
212 |
| 2017-03-31 |
216 |
| 2016-12-31 |
219 |
| 2016-09-30 |
219 |
| 2016-06-30 |
219 |
| 2016-03-31 |
219 |
| 2015-12-31 |
231 |
| 2015-09-30 |
233 |
| 2015-06-30 |
236 |
| 2015-03-31 |
236 |
| 2014-12-31 |
237 |
| 2014-09-30 |
237 |
| 2014-06-30 |
237 |
| 2014-03-31 |
238 |
| 2013-12-31 |
238 |
| 2013-09-30 |
238 |
| 2013-06-30 |
239 |
| 2013-03-31 |
238 |
| 2012-12-31 |
240 |
| 2012-09-30 |
238 |
| 2012-06-30 |
241 |
| 2012-03-31 |
242 |
| 2011-12-31 |
245 |
| 2011-09-30 |
245 |
| 2011-06-30 |
245 |
| 2011-03-31 |
245 |
| 2010-12-31 |
255 |
| 2010-09-30 |
242 |
| 2010-06-30 |
262 |
| 2010-03-31 |
273 |
| 2009-12-31 |
289 |
| 2009-09-30 |
291 |
| 2009-06-30 |
290 |
| 2009-03-31 |
290 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$29.239B |
$10.982B |
|
Biogen Inc. is one of the world's leading biotechnology companies which focuses on developing innovative therapies for treating serious neurological and neurodegenerative diseases, including its core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement disorders including Parkinson's disease, neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS) and ophthalmology. Key multiple sclerosis/MS drugs in its portfolio are Tecfidera, Vumerity, Avonex, Plegridy, Fampyra and Tysabri. Other approved/marketed products include Fumaderm (severe psoriasis), Spinraza (spinal muscular atrophy (SMA)) and Aduhelm (Alzheimer's disease).
|
